购物车
- 全部删除
- 您的购物车当前为空
Theralizumab (TGN1412) 是一种抗靶向 CD28 的单克隆抗体,可直接刺激 T 细胞。Theralizumab 具有抗肿瘤活性,用于治疗 B 细胞慢性淋巴细胞白血病和类风湿性关节炎。
为众多的药物研发团队赋能,
让新药发现更简单!
Theralizumab (TGN1412) 是一种抗靶向 CD28 的单克隆抗体,可直接刺激 T 细胞。Theralizumab 具有抗肿瘤活性,用于治疗 B 细胞慢性淋巴细胞白血病和类风湿性关节炎。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,880 | 现货 | |
5 mg | ¥ 6,570 | 现货 | |
10 mg | ¥ 8,860 | 现货 | |
25 mg | ¥ 12,900 | 现货 | |
50 mg | ¥ 17,700 | 现货 |
产品描述 | Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the treatment of B-cell chronic lymphocytic leukemia and rheumatoid arthritis. |
别名 | TGN1412, TABO8, TAB-08 |
CAS No. | 906068-56-2 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容